Form D · Biotechnology
CytoDel, INC.
New York, NY · CIK 0001705194
Offering snapshot reported Jan 17, 2018 · SEC filing
- Reported sold
- $3.91M Offering amount: $6.15M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Jan 5, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 17, 2018 | Initial | $3,905,000 | No comparison | 11 | SEC filing |
| Apr 28, 2017 | Initial | $150,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-303381
As per the definitive offering documents, certain of the investors shall purchase, and the issuer shall sell, shares of preferred stock having a purchase price equal to the total remaining to be sold upon the satisfaction of certain milestones.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| NONE | None |
Source: Form D, filed Jan 17, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Philip A. Band | Director, Executive |
| Margery Fischbein | Director |
| Andre Gudger | Director |
| Charles Weiss | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
423 West 127 Th Street
New York, NY, 10027
New York, NY, 10027